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Charcot-Marie-Tooth type 4 (CMT4) is an autosomal recessive severe form of neuropathy
with genetic heterogeneity. CMT4B1 is caused by mutations in the myotubularin-related
2 (MTMR2) gene and as a member of the myotubularin family, the MTMR2 protein
is crucial for the modulation of membrane trafficking. To enable future clinical trials,
we performed a detailed review of the published cases with MTMR2 mutations and
describe four novel cases identified through whole-exome sequencing (WES). The four
unrelated families harbor novel homozygous mutations in MTMR2 (NM_016156, Family
1: c.1490dupC; p.Phe498IlefsTer2; Family 2: c.1479+1G>A; Family 3: c.1090C>T;
p.Arg364Ter; Family 4: c.883C>T; p.Arg295Ter) and present with CMT4B1-related
severe early-onset motor and sensory neuropathy, generalized muscle atrophy, facial
and bulbar weakness, and pes cavus deformity. The clinical description of the new
mutations reported here overlap with previously reported CMT4B1 phenotypes caused
by mutations in the phosphatase domain ofMTMR2, suggesting that nonsenseMTMR2
mutations, which are predicted to result in loss or disruption of the phosphatase
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domain, are associated with a severe phenotype and loss of independent ambulation
by the early twenties. Whereas the few reported missense mutations and also those
truncating mutations occurring at the C-terminus after the phosphatase domain cause
a rather mild phenotype and patients were still ambulatory above the age 30 years.
Charcot-Marie-Tooth neuropathy and Centronuclear Myopathy causing mutations have
been shown to occur in proteins involved in membrane remodeling and trafficking
pathway mediated by phosphoinositides. Earlier studies have showing the rescue of
MTM1 myopathy by MTMR2 overexpression, emphasize the importance of maintaining
the phosphoinositides equilibrium and highlight a potential compensatory mechanism
amongst members of this pathway. This proved that the regulation of expression of
these proteins involved in the membrane remodeling pathway may compensate each
other’s loss- or gain-of-functionmutations by restoring the phosphoinositides equilibrium.
This provides a potential therapeutic strategy for neuromuscular diseases resulting from
mutations in the membrane remodeling pathway.
Keywords: Charcot-Marie-Tooth disease type 4B1, myotubularin-related 2 gene, whole-exome sequencing,
phosphoinositides, membrane remodeling
INTRODUCTION
Charcot-Marie-Tooth disease (CMT) is a clinically and
genetically heterogeneous group of hereditary disorders
characterized by chronic degenerative neuropathy of the
peripheral nervous system. It is one of the most common causes
of peripheral neuropathy affecting at least 1 in every 2,500 people
(Szigeti and Lupski, 2009), with more than 80 disease-causing
genes being identified (Previtali et al., 2007). CMT4B is a
severe autosomal recessive neuropathy with demyelination
and myelin outfoldings of the nerve and is classified into two
subgroups: CMT4B1 (Bolino et al., 2000) (MTMR2 mutations,
OMIM 601382) and CMT4B2 (MTMR13 mutations, OMIM
604563). Patients with CMT4B1 have a severe early-onset of
disease and are characterized by demyelinating sensorimotor
polyneuropathy with irregular redundant loops of focally
folded myelin seen in nerve biopsy, called myelin outfoldings
(Quattrone et al., 1996).
MTMR2 encodes the Myotubularin Related Protein 2
(MTMR2) which is part of the large myotubularin family
crucially implicated in the modulation of cellular membrane
trafficking. In mammals, the myotubularin family has 14
members, MTM1 and MTMR1-13. They all feature a conserved
PTP-like (protein tyrosine phosphatase-like) and PH-GRAM
(pleckstrin homology- Glucosyltransferases, Rab-like GTPase
activators, and Myotubularins) domains (Begley et al., 2003).
Among the 13 MTMRs, seven are inactive phosphatases due
to substitutions of conserved amino acids for active catalysis,
but they can heterodimerize with the active forms for activity
regulation (Zou et al., 2012).
MTMR2 is highly expressed in motor and sensory neurons,
regulating membrane homeostasis in Schwann cell myelination
(Quattrone et al., 1996; Bolino et al., 2000). Limited genotype-
phenotype correlations are available for CMT4B1, due to the
restricted number of patients carrying MTMR2 mutations that
have been reported to date and lack of scientific interest. Thus,
far no specific treatment for CMT4B1 exists.
Both CMT4B1 and Centronuclear myopathy (CNM) are
caused by mutations in a set of proteins involved in membrane
remodeling, suggesting they may have shared pathological
pathways (Cowling et al., 2012), and that there may be some
redundancy allowing compensation for the loss of function by
restoring the balance of enzyme activities (Raimondi et al., 2011;
Raess et al., 2017). Indeed, the rescue of MTM1 myopathies by
MTMR2 overexpression has recently been demonstrated (Raess
et al., 2017; Danièle et al., 2018).
In this study, we report four different novel MTMR2
homozygous mutations in four unrelated families with severe
clinical presentation, with all four mutations in the phosphatase
domain of MTMR2. Through evaluation of the clinical and
genetic spectrum of all up to date (beginning of 2019)
reportedMTMR2 related CMT4B1 cases and correlation between
phenotype and genotype, we provide guidance for genetic and
clinical diagnosis forMTMR2-related CMT4B1.
MATERIALS AND METHODS
Patients
We report four unrelated families from Turkey, Afghanistan, and
Iran, comprising of three, three, two and one affected siblings,
respectively, all born to consanguineous parents. Patients from
family 1 were referred to the University of Health Sciences,
Kayseri City Hospital, Department of Pediatric Neurology,
Kayseri, Turkey. Patients from family 2 were referred to Dr.
Shalbafans private clinic in Ahvaz, Iran. The siblings of family
3 were referred to Narges Medical Genetics and Prenatal
Diagnosis Laboratory, Ahvaz, Iran for genetic counseling and
diagnosis. A 5-year-old female from family 4 was referred to the
Department of Pediatric Neurology, Institute of Child Health
and The Children’s Hospital Lahore, Pakistan. Consent was
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obtained individually, and routine diagnosis and related studies
were approved by the respective institutional ethical boards in
Cologne/Germany, Ahvaz Jundishapur University of Medical
Sciences/Iran, the Institute of Child Health and The Children’s
Hospital Lahore/Pakistan.
Exome Sequencing
The institutional ethical board of University of Cologne approved
the study and informed consent was obtained from the parents.
Whole exome sequencing (WES) of an index patient from each
family was carried out (experimentalWES details for each patient
listed in the Supplementary Material).
We used the best-practice filtering scheme based on the
autosomal-recessive inheritance from the pedigrees (Figure 2)
(as previously described in Seelow and Schuelke, 2012; Lupski
et al., 2013; Sprute et al., 2019) and evaluated variants using
the American College of Medical Genetics and Genomics
(ACMG) guidelines and established variant databases for variant
interpretation [Mutation Taster (http://www.mutationtaster.
org/), gnomAD (http://gnomad.broadinstitute.org/gene/),
ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/), GME (http://
igm.ucsd.edu/gme/data-browser.php), and ExAc (http://exac.
broadinstitute.org)]. The mutations were further evaluated with
established prediction tools MutPred2, SIFT, PolyPhen, and
PhyloP scores (Richards et al., 2015). Dideoxy sequencing was
performed for confirmation and cosegregation of variants in
available family members.
Pathway Analysis
We used Cytoscape stringapp for StringDB interaction network
analysis (von Mering et al., 2005; Doncheva et al., 2019). The
String database consists of PPI information from experimental
data, functional associations from curated pathways, text
mining from publications and predictions. The probabilistic
scores from each functional association are combined with
a confidence score for each PPI and corrected for randomly
observed interactions. Seven neuromuscular disease-associated
genes involved in membrane remodeling (n = 7) were selected
for the analysis (Figure 4). The top 20 interactors with the
highest confidence scores were added to the dataset. Note
that all analysis details including the enriched terms from
different databases as well as PIMDs (interaction evidence),
PPI interaction between every 2 nodes, related p-values, and
genes included for each enriched term are exported in the
spreadsheet tables (Supplementary Table 1 EdgeTable and
Supplementary Table 2 StringTable). The network maps
represent a short summary of these tables: the colored donut
slices which surround each node represent the most significant
eight interactions of the enriched data in which that gene
(node) was found. The color codes can also be found in the
Supplementary Table 2 String Table. The over-representation
analysis (ORA) was performed for Gene Ontology (GO)
Cellular Component (GO:CC) (Supplementary Table 3),
Biological Process (GO:BP, Supplementary Table 4), Molecular
Function (GO:MF, Supplementary Table 5) classes (Boyle
et al., 2004) via R-cluster profile library (Yu et al., 2012).
Hypergeometric distribution was used to calculate the p-
values. False discovery rates (FDR) were calculated via the
Benjamini-Hochberg method. A total of 27 genes (7 selected
neuromuscular disease-associated genes in addition to 20 the
most significant genes according to interactome analysis).
The FDR adjusted p-values below 0.05 accepted as statistically
significant GO terms. More details on the ORA can be found in
the Supplementary Material.
RESULTS
Clinical Description
Family 1
Three Turkish siblings, one female and two males
(Figures 1A–C), were referred to our clinic with complaints of
severe generalized muscle weakness and motor developmental
delay. All patients were born at term after an uneventful
pregnancy via uncomplicated vaginal delivery without having
any postnatal problems. Their parents were first-degree
consanguineous, having three affected children among
a total of nine. All three patients developed symptoms
with slow progression after reaching the age of 3 years (see
Supplementary Materials for detailed clinical description and
Supplementary Videos 1–3) (Neyzi et al., 2015). Their tendon
reflexes were absent in upper and lower extremities, without
any pathological reflexes (Medical Research Council, 1976).
Biochemical tests including a complete blood count, liver and
kidney function tests, serum electrolyte levels, tests for common
inborn errors of metabolism, thyroid function tests, and muscle
creatine kinase levels revealed normal values. Brain and spine
MRI results were not pathological. Electrophysiological studies
showed severe demyelinating sensorimotor polyneuropathy
(Tables 1, 2).
Family 2
Three Afghani siblings, one male and two females (Figure 1D
and Supplementary Figures 1A,B), presented with complaints
of severe generalized muscle weakness. Their parents were
first-degree relatives, with three affected and three unaffected
children. All patients were born at term after an uneventful
pregnancy via uncomplicated vaginal delivery without any
postnatal problems. Their tendon reflexes were absent in
upper and lower extremities, without any pathological
reflexes (see Supplementary Materials for detailed clinical
description and Supplementary Figure 1). Biochemical tests
including a common test for inborn errors of metabolism,
thyroid functions, and muscle creatine kinase levels revealed
values in the normal range. Brain and spine MRI results
were normal. Electrophysiological studies showed severe
demyelinating sensorimotor polyneuropathy (Table 1 and
Supplementary Figure 2).
Family 3
Two siblings, one female, and one male, were born to a
consanguineous family in Iran, who presented with skeletal
defects andmotor disabilities. Both patients were born via normal
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FIGURE 1 | Clinical hallmarks. (A) The clinical picture of patient family 1 II.1 at the age of 18 years showing generalized muscle atrophy, facial weakness, and mild
pectus carinatum. (B) Clinical presentation of patient family 1 II.2 at the age of 17 years with facial weakness, progressive neuropathic muscular atrophy in the hands
and pes cavus foot deformities. (C) Patient family 1 II.3 at the age of 12 years presenting with thoracic kyphosis, progressive neuropathic muscular atrophy in the
hands, mild pectus carinatum and pes cavus foot deformities. (D) Clinical presentation of patient II.3 from family 2 showing facial weakness, clenched hands, club
feet, and glaucoma. (E,F) Clinical hallmarks from the affected individuals in Family 3 illustrate the skeletal deformities. (E) Distal muscle atrophy, claw hand deformities,
hammertoes, and foot deformities in the wheelchair-bound bound girl (Family 3, Patient II.2). (F) Distal muscle atrophy, claw hand deformities, and foot drop in the
elder brother (Family 3, Patient II.1). (G) Clinical presentation of patient family 4 II.3 showed pes cavus foot deformity and muscle weakness and atrophy mainly
involving the lower extremity muscles.
vaginal delivery and appeared normal at birth without any
remarkable complaints.
Patient II.2 from family 3 is a 20-year-old male. He presented
with delayed walking at the age of 2 years. From the age
of four, he began to progressively show signs of neuropathic
symptoms including muscle weakness, foot drop, pes cavus,
hammertoes, and claw hand deformities. He was exhibiting
a steppage gait (Figure 1F and Supplementary Video 4). The
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TABLE 1 | Clinical, electrophysiological, and molecular genetic characteristics of the sibling patients from family 1, 2, 3, and 4.
Findings Family 1 patient
II.1
Family 1 patient
II.2
Family 1 patient
II.3
Family 2 patient
II.1
Family 2 patient
II.3
Family 2 patient
II.4
Family 3 patient
II.1
Family 3 patient
II.2
Family 4 patient
II.3
Age/Gender 18 years†/Male 18 years/Female 12 years/Male 29 years/Female 26 years/Female 24 years/Male 20 years/Male 18 years/Female 5 years/Female
Age of symptom
onset
4 years 4 years 4 years 7 years 1.5 years 6 years 4 years 5 years First months of life
Growth
development
Height and Weight
<3rd percentile
Height and Weight
<3rd percentile
Height and Weight
<3rd percentile
Height and Weight
<3rd percentile
Height and Weight
<3rd percentile
Height and weight
normal
Height and Weight
<3rd percentile
Height and Weight
<3rd percentile
Not elicited
Muscles strength
(MRC grade)
Upper limbs:
3/5 in proximal,
and 2/5 in distal
Lower limbs:
0/5 in proximal
and distal
Upper limbs:
4/5 in proximal,
and 3/5 in distal
Lower limbs:
4/5 in proximal,
and 3/5 in distal
Upper limbs:
5/5 in proximal,
and 4/5 in distal
Lower limbs:
5/5 in proximal;
4/5 in the left
distal, and 3/5 in
the right distal
Upper limbs:
5/5 in proximal,
and 4/5 in distal
Lower limbs:
5/5 in proximal;
4/5 in the left
distal, and 3/5 in
the right distal
Upper limbs:
4/5 in proximal,
and 0/5 in distal
Lower limbs:
0/5 in proximal;
0/5 in distal
Upper limbs:
5/5 in proximal,
and 5/5 in distal
Lower limbs:
5/5 in proximal;
2/5 in distal
Not elicited Not elicited Not elicited
DTRs Absent Absent Absent Absent Absent Absent Absent Absent Absent
Gait Wheelchair-bound
at age 17
Wheelchair-bound
at age 18
Walk without
support
Wheelchair-bound
at age 15
Wheelchair-bound
at age 15
Walk without
support
Steppage gait Wheelchair-bound Walk without
support
Electrophysical findings
Ulnar MAP at wrist
(m/V)
Not elicited Not elicited 1.1 Absent response Absent response Absent response Not elicited Not elicited Not elicited
Ulnar MCV at wrist
(m/s)
Not elicited Not elicited 8.15 Absent response Absent response Absent response Not elicited Not elicited Not elicited
Ulnar SNAP at
wrist (µV)
Absent response Absent response Absent response 9.6 (norm>15) Absent response Absent response Not elicited Not elicited Not elicited
Ulnar SCV at wrist
(m/s)
Absent response Absent response Absent response 34 (norm>38) Absent response Absent response Not elicited Not elicited Not elicited
Ulnar MAP below
elbow (m/V)
Not elicited Not elicited 0.6 Absent response Absent response Absent response Not elicited Not elicited Not elicited
Ulnar MCV below
elbow (m/s)
Not elicited Not elicited 20.2 Absent response Absent response Absent response Not elicited Not elicited Not elicited
Ulnar SNAP below
elbow (µV)
Absent response Absent response Absent response 8.5 (norm>10) Absent response Absent response Not elicited Not elicited Not elicited
Ulnar SCV below
elbow (m/s)
Absent response Absent response Absent response 33 (norm>39) Absent response Absent response Not elicited Not elicited Not elicited
Tibial MAP (mV) Not elicited Not elicited 1.2 Not elicited Not elicited Not elicited Not elicited Not elicited Not elicited
Tibial MCV (m/s) Not elicited Not elicited 8.95 Not elicited Not elicited Not elicited Not elicited Not elicited Not elicited
Tibial SNAP (µV) Absent response Absent response Absent response Not elicited Not elicited Not elicited Not elicited Not elicited Not elicited
Tibial SCV (m/s) Absent response Absent response Absent response Not elicited Not elicited Not elicited Not elicited Not elicited Not elicited
†
Passed away; DL, distal latency; DTR, deep tendon reflex; MAP, compound muscle action potential; MCV, motor conduction velocity; MRC, Medical Research Council Grades for Muscle Strength; SNAP, sensory nerve action potential;
SCV, sensory conduction velocity.
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TABLE 2 | Overview of MTMR2 related Charcot-Marie-Tooth disease type 4B1.
References Age/Gender
(M/F)
Age at onset
(months)
Nerve
palsy
Skeletal
deformities
Systemic problems Demyelinating
PNP
MTMR2 mutation
Houlden et al.,
2001
16 years/M 13 Vocal No Stridor, Dysarthria Yes c.308G>A;
p.Gly103Glu
5 years/M 12 No No No No c.324del;
p.Asp109IlefsTer17
Nelis et al., 2002 10 years/M 24 No No No Yes c.847C>T;
p.Arg283Trp
16 years/F 24 No No No No c.847C>T;
p.Arg283Trp
Verny et al., 2004 18 years/F Birth No Pes equinovarus Dysarthria, respiratory
difficulties
Yes c.1749G>A;
p.Trp583Ter
Parman et al.,
2004
21 years/F Delayed motor
milestones
No Pes cavus, claw
hands, scoliosis
Hypophonia Yes c.681_682ins(446);
p.Thr228fsTer275
24 years/F No Pes cavus,
hammer toe
Hypophonia, tremor Yes c.841_844del;
p.Ile281LeufsTer10
Nouioua et al.,
2011
16 years/M 24 Vocal,
facial
Pes equinovarus,
claw hands, chest
Stridor Yes c.331dup;
p.Arg111LysfsTer24
12 years/M 24 Vocal,
facial
Claw hands, chest Stridor Yes c.331dup;
p.Arg111LysfsTer24
9 years/M 12 Vocal,
facial
Pes equinovarus,
claw hands, chest
Stridor Yes c.331dup;
p.Arg111LysfsTer24
Luigetti et al.,
2013
48 years/M No data No No Facial weakness No c.1534del;
p.Leu512TyrfsTer33
30 years/F No data No No Respiratory failure Yes c.1534del;
p.Leu512TyrfsTer33
Murakami et al.,
2013
30 years/F 156 No Claw hands No Yes c.1882_1885del;
p.Arg628ProfsTer18
Scott et al., 2016 28 years/M 48 No Claw hands Facial weakness, optic
neuritis, cervical
Schwannoma
Yes c.1768C>T;
p.Gln590Ter
Zambon et al.,
2017
3 years/F 12–18 Vocal Pes planus,
foot-drop
Facial weakness,
hoarseness, stridor,
dysphagia
Yes c.484 C>T;
p.Arg162Ter
Abdalla-Moady
et al., 2018
31 years/F 132 No Pes cavus No No data c.1877_1878insAGAG,
p.Ala629GlufsTer31
Current report:
Family I 3 siblings
18 years/M 48 Vocal Pes cavus, mild
pectus carinatum,
thoracic kyphosis
Facial weakness,
dysphagia, speech
impairment, adenoid
hypertrophy, arytenoid
subluxation, myopic
refractive error
Yes c.1490dupC;
p.Phe498IlefsTer2
17 years/F 48 Vocal Pes cavus, mild
pectus carinatum
Facial weakness,
dysphagia, speech
impairment, adenoid
hypertrophy, arytenoid
subluxation, myopic
refractive error
Yes c.1490dupC;
p.Phe498IlefsTer2
12 years/M 48 No Pes cavus, mild
pectus carinatum,
thoracic kyphosis
Facial weakness, speech
impairment, adenoid
hypertrophy, hypoplastic
arytenoid cartilages with
medial deviation
Yes c.1490dupC;
p.Phe498IlefsTer2
Current report
Family II 3 siblings
29 years/F 84 No Pes cavus, pectus
carinatum,
thoracic kyphosis
Facial weakness, severe
dysphonia dysphagia,
respiratory attacks
Yes Splice site
c.1479+1G>A
26 years/F 18 No Pes cavus, club
feet, clenched
hands
Facial weakness, bulbar
muscle weakness, bilateral
glaucoma with loss of vision
Yes Splice site
c.1479+1G>A
(Continued)
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TABLE 2 | Continued
References Age/Gender
(M/F)
Age at onset
(months)
Nerve
palsy
Skeletal
deformities
Systemic problems Demyelinating
PNP
MTMR2 mutation
24 years/M 72 No Pes cavus Mild facial weakness,
moderate dysphonia,
seizures
Yes Splice site
c.1479+1G>A
Current report
Family III 2 siblings
20 years/M 48 No Pes cavus, mild
scoliosis, hammer
toes, foot drop,
claw hands
Dysphonia Yes c.1090C>T;
p.Arg364Ter
18 years/F 60 No Pes cavus, severe
scoliosis, hammer
toes, foot drop,
claw hands
Facial weakness No data c.1090C>T;
p.Arg364Ter
Current report
Family IV 1 sibling
5 years/F First months of
life
No Pes cavus Yes c.883C>T;
p.Arg295Ter
F, female; M, male; PNP, Polyneuropathy; EMG, Electromyography.
A PubMed/Medline search (1966–2019) of “Charcot-Marie-Tooth disease AND MTMR2 mutation” and “Charcot-Marie-Tooth disease type 4B1.” Cohort of Pareyson et al. was not
included due to overlapping of the reviewed cases and the absence of a clear phenotypic assignment of the novel cases. MTMR2 reference sequence (NM_016156).
electrophysiological studies at 5–6 years were compatible with
a demyelinating sensorimotor neuropathy. The latest clinical
exam confirmed that he developed distal and proximal limb
muscle atrophy, mild scoliosis, and an abnormal voice that
reflects the involvement of laryngeal muscles. However, his
cognition was normal and he had no facial weakness. Patient
II.1 from family 3 is a wheelchair-bound 18-year old female
(Figure 1E) who presented with peripheral nervous system and
skeletal abnormalities and had a symptom onset at 5 years.
The latest neurological examination demonstrated that specific
symptoms and disease progression were similar to her older
brother (Table 1), although the severity of the disease was much
more serious compared to him. Furthermore, she has shown
facial weakness.
Family 4
Patient II. 3 from family 4 is a 5-year-old female with a
history of weakness and motor developmental delay (including
delay in sitting and crawling) from the first months of life
and a pes cavus foot deformity. Her healthy parents are
Pakistani second-degree cousins from the region of Punjab.
She started walking at the age of 2 years. Her presentation
was resembling a motor polyneuropathy with progressive
deterioration. Neurological examination revealed a pes
cavus foot deformity and muscle weakness and atrophy
mainly involving the lower limb muscles (Figure 1G).
Deep tendon reflexes were absent. Her healthy parents
were Pakistani second-degree cousins from the region
of Punjab.
Genomic Results
Exome sequencing revealed a homozygous c.1490dupC;
p.Phe498IlefsTer2 mutation in MTMR2 (NM_016156) in the
index patient of family 1, that was found to co-segregate; a
homozygous splice site mutation c.1479+1G>A in MTMR2
co-segregating in family 2; a homozygous nonsense mutation
c.1090C>T; p.Arg364Ter in MTMR2 co-segregating in family
3 which lies in an extended region of homozygosity that spans
52.47Mb; and a homozygous nonsense mutation in MTMR2
(c.883C>T; p.Arg295Ter) co-segregating in family 4. These
variants have not been previously described nor published
elsewhere to be associated with CMT4B1 and were confirmed via
dideoxy sequencing to be co-segregating with the phenotype in
the four families (Figure 2).
In family 1, both parents were confirmed to be heterozygous
carriers for the same mutation. For family 2, a DNA sample
of the father was not available, but the mother carries the
same heterozygous variant as her affected children do in the
homozygous state. The parents in family 3 and 4 were also
confirmed to be heterozygous carriers for the same mutation as
their children.
Three of four novel mutations from our study are predicted to
result in non-sense mediated decay, the c.1490dupC; c.1090C>T;
c.883C>T. Following NMD exclusion guidelines suggested by
Popp and Maquat (2016): the premature stop codon should be
located 50–55 or fewer nucleotides upstream of an exon-exon
junction to prevent NMD. That is not the case for these three
mutations, whose stop codon location did not meet the criteria to
prevent NMD, thus they are very likely to be degraded by NMD.
However, this prediction still requires experimental validation.
DISCUSSION
Myotubularin (MTM1) and MTM related proteins (MTMRs)
belong to the large subfamily of protein tyrosine phosphatases
(PTPs). Mutations in MTMR2 underlie autosomal recessive
CMT4B1. MTMR2 consists of a PH-GRAM (pleckstrin
homology- Glucosyltransferases, Rab-like GTPase activators
and Myotubularins) domain, a phosphatase domain, one
coiled-coil and a PDZ-binding motif (Begley et al., 2003;
Figure 3). It has four isoforms in mice. The longest isoform
(MTMR2-L) has a longer N-terminal sequence before the
PH-GRAM domain compared to the shortest one (MTMR2-S).
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FIGURE 2 | Genomic analysis revealed an individual mutation in MTMR2 gene. The genealogy of the family and the MTMR2 electropherograms show the same novel
homozygous c.1490dupC; p.Phe498IlefsTer2 mutation identified in all three siblings in family 1 (A) and a homozygous c.1479+1G>A splice site mutation in family 2
(B) and in family 3 (C) a homozygous c.1090C>T; p.Arg364Ter stop mutation and in family 4 (D) a homozygous c.883C>T; p.Arg295Ter mutation in the MTMR2 gene
was revealed. Parents were heterozygous for the same mutation as their children in all three families.
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FIGURE 3 | Schematic representation of human MTMR2 protein domains (NP 057240.3) and position of the mutations identified so far, generated by Illustrator for
Biological Sequences: IBS. In red are the reported novel mutations identified in our study. The MTMR2 long isoform (MTMR2-L), MTMR2 short isoform (MTMR2-S),
and MTM1, all contain (Raess et al., 2017) PH-GRAM domain, phosphatase domain, Coiled-Coil domain, and PDZ binding motif. The two MTMR2 protein isoforms
differ only in their translation start sites.
MTMR2 can dephosphorylate both Phosphatidylinositol 3-
phosphate (PtdIns3P) and Phosphatidylinositol 3,5-bisphosphate
[PtdIns(3,5)P2; (Begley et al., 2003)], which are regulators of
membrane homeostasis and vesicle transport. Disruption
of PtdIns(3,5)P2 homeostasis, which is maintained by two
phosphatases MTMR2 and FIG4 (Factor-Induced Gene 4),
is linked to altered longitudinal myelin growth and myelin
outfolding formation and is believed to be the mechanism for
MTMR2mutations causing CMT4B1 (Vaccari et al., 2011).
CMT4B1 is characterized by severe progressive distal and
proximal muscular weakness in early childhood, initially starting
at the lower limbs, as well as sensory loss and decreased nerve
conduction velocity (Quattrone et al., 1996; Bolino et al., 2000;
Houlden et al., 2001; Parman et al., 2004; Verny et al., 2004;
Nouioua et al., 2011; Scott et al., 2016). We report nine children
from four unrelated families with a typical CMT4B1 phenotype
of severe early-onset motor and sensory neuropathy. Distal
muscle weakness was distinct in all our patients. Sensory nerve
action potentials and nerve conduction velocity could not be
detected in any of the cases of family 1. Compoundmuscle action
potential and motor conduction velocity could be measured
only in patient II.3 from family 1 at severely reduced levels
(Table 1). In agreement with most previously reported cases of
CMT4B1 (Bolino et al., 2000; Houlden et al., 2001; Parman
et al., 2004; Verny et al., 2004; Nouioua et al., 2011; Murakami
et al., 2013; Scott et al., 2016), our cases were also sired by
consanguineous parents.
As the disease progresses, patients usually lose mobility
and become wheelchair-bound by the second or third decade
of their lives. One of our patients (family 1 II.1) died at
the age of 18 years, and three others had a severe motor
impairment and were wheelchair-bound since the age of 15
years. Pes cavus deformity was frequently reported in previous
studies (Parman et al., 2004; Verny et al., 2004; Nouioua
et al., 2011). In the present study, pes cavus deformity was
diagnosed in all nine patients and became progressively worse,
frequently requiring surgery in the first decade of their lives.
Other associated clinical features are developmental delay, facial
weakness, claw hands, chest deformity, kyphosis, scoliosis,
facial palsy, deafness, schwannoma, optic neuritis, vocal cord
palsy, dysarthria, dysphagia, hypophonia, stridor, and respiratory
insufficiency (compare Tables 2, 3) (Quattrone et al., 1996;
Bolino et al., 2000; Houlden et al., 2001; Nelis et al., 2002; Parman
et al., 2004; Verny et al., 2004; Nouioua et al., 2011; Luigetti et al.,
2013; Murakami et al., 2013; Scott et al., 2016; Zambon et al.,
2017; Abdalla-Moady et al., 2018).
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TABLE 3 | Clinical phenotype of patients with MTMR2 related
Charcot-Marie-Tooth disease.
Clinical findings Frequency
Skeletal deformities
Chest deformities 7/25 (28%)
Thoracic kyphosis 3/25 (12%)
Scoliosis 3/25 (12%)
Hand deformities
Claw hands 8/25 (32%)
Clenched hands 1/25 (4%)
Foot deformities
Pes cavus 12/25 (48%)
Pes equinovarus 3/25 (12%)
Pes planus 1/25 (4%)
Bulbar/laryngeal findings
Facial palsy 3/25 (12%)
Facial weakness 10/25 (40%)
Dysphagia 5/25 (20%)
Vocal palsy 7/25 (28%)
Respiratory difficulties 8/25 (32%)
Stridor 5/25 (20%)
Speech impairment 11/25 (44%)
Adenoid hypertrophy 3/25 (12%)
Arytenoid subluxation 2/25 (8%)
Hypoplastic arytenoid 1/25 (4%)
Eye disease 4/25 (16%)
Myopic refractive error 2/25 (8%)
Optic neuritis 1/25 (4%)
Glaucoma 1/25 (4%)
Further clinical findings
Cervical schwannoma 1/25 (4%)
Seizures 1/25 (4%)
In family 1, the frameshift MTMR2 mutation
p.Phe498IlefsTer2 is located in the protein tyrosine phosphatase
domain and causes a severe form of CMT4B1. All affected family
members developed muscle atrophy and facial weakness at the
end of the first decade. During the follow-up period, patients
II.1 and II.2 from family 1 developed dysphagia and all three
siblings had a speech impairment. Additionally, snoring was
observed in patient II.1, probably due to adenoid vegetation
or arytenoid subluxation and vocal cord paralysis. These two
patients represent the first CMT4B1 cases with protein tyrosine
phosphatase domain mutations and vocal cord paralysis. The
mutation in this family is predicted to result in partial loss of the
phosphatase domain (impact on activity) and loss of the entire
C-terminal region including the coiled-coil for dimerization
(further impact on activity) and membrane association as well
as the PDZ binding motif, most likely leading to the severity of
the phenotype.
Interestingly, there were hypoplastic arytenoid cartilages with
medial deviation and arytenoid subluxation in the patients from
family 1. Our findings suggest that arytenoid abnormalities
whether or not coupled with vocal cord paralysis due to unknown
causes may be associated with the hereditary neuropathy. Vocal
cord paralysis has previously been reported with CMT4B1
(Houlden et al., 2001; Nouioua et al., 2011; Zambon et al., 2017).
All patients suffered from severe demyelinating neuropathy
with respiratory problems. In the present study, vocal cord
paralysis developed in patients II.1 and II.2 from family 1. It
presented as a late symptom in contrast to previously reported
cases (Nouioua et al., 2011; Zambon et al., 2017). Adenoidal
vegetation and myopic refractive error are common problems
in childhood. The coexistence of these disorders and CMT4B1
may be coincidental in our patients. On the other hand, tonsillitis
and adenoidal vegetation must be followed closely to prevent
upper airway obstruction in CMT4B1 patients, particularly if
they have vocal cord paralysis. It should not be forgotten that
in such a clinical condition a mild upper airway infection might
have lethal consequences.
In family 2, the homozygous splice-site mutation likewise
causes a severe phenotype in the affected siblings. All children
developed walking difficulties within their first decade of life
and two of them became wheelchair-bound at the age of 15
years. Interestingly, their younger brother (case II.4 of family
2) had a milder clinical course with similar age of onset
but a less progressive course, despite having the identical
homozygous pathogenic variant as his siblings. With 24 years,
he is still able to walk without support, he has no respiratory
difficulties and no dysphagia, and his weight and height are
within the reference range. On the other hand, he suffered
from seizures in his first decade of life. Furthermore, one of
the sisters (II.2 of family 2) developed loss of vision due to
bilateral glaucoma, a symptom that was not described yet in
CMT4B1 patients but has been seen in CMT4 subtype B2 which
is caused by mutations in MTMR13 (Pareyson et al., 2019).
Nevertheless, it should be noted, that without evidence from
additional cases association of CMT4B1 with glaucoma could be
a consequence of additional pathogenic variants in a different
gene harbored by this affected family member, particularly given
the consanguinity.
Thus, we demonstrate in family 2 intra-familial phenotypic
variability in regard to the disease course and severity,
implicating other factors such as access to high-quality
medical care (e.g., environmental modifications, modifier
genes, epigenetic alterations) in the clinical outcomes. This
variability highlights a promising area of future research
aimed at understanding the role of modulatory and
environmental factors which contribute to the phenotypes.
Due to the limited access to high-quality medical care these
families represent the unmitigated natural disease course of
the disease.
In family 3, all patients carry a nonsense mutation
p.Arg364Ter predicted to result in a truncated protein with loss
of substantial part of the phosphatase domain, causing also a
severe phenotype in the affected siblings. Both affected siblings
developed muscle atrophy at the end of their first decade. In
this family, we can also see a phenotypic variability in the
symptoms and differences in the disease course despite both
siblings harboring the identical pathogenic variant. The older
brother is still able to walk at the age of 20 years while his
younger sister is already wheelchair bound and is also suffering
from facial weakness. Nevertheless, the age of onset was similar
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to previously reported cases and both children are suffering
from muscle weakness, skeletal deformities, and early onset
sensorimotor neuropathy, thus exhibiting typical symptoms of
theMTMR2-related disease.
Interestingly, in both families 2 and 3 the female siblings
seem to suffer from a more severe disease course than their male
siblings with the same disease-causing mutation.
Similar to family 3, the patient II.3 of family 4 carries
a nonsense mutation, p.Arg295Ter predicted to result in a
truncated protein with loss of major part of the phosphatase
domain, thus also associated with a severe phenotype. The
patient exhibited first symptoms of the disease even earlier than
reported in the other cases, within the first months of her life.
The disease course is not yet comparable due to the young
age of the patient, but she already has motor developmental
delay and pes cavus deformity which developed by the age of
5 years.
In the previously reported cases (Table 2); the mean age at the
time of diagnosis was 3.5± 3.7 years (range: 0–13 years). All cases
presented with motor and sensory polyneuropathy with different
clinical features and progression. So far, four mutations occur in
the PH-GRAM domain, five mutations occur in the phosphatase
domain, two in the linker area between the phosphatase domain
and the following coiled-coil, two in the PDZ-binding motif
(Figure 3). Among the four PH-GRAM domain mutations, three
of them (p.Asn109IlefsTer17, p.Arg111LysfsTer24, p.Arg162Ter)
are predicted to result in a truncated form of MTMR2 lacking the
entire phosphatase domain, and except for the patient carrying
p.Asn109IlefsTer17 with mild phenotype who is still young (5
years old), the other two already have a severe phenotype (facial
weakness, stridor, dysphagia, skeletal deformities, vocal cord
paralysis, and facial nerve palsy) corresponding to the predicted
loss of enzymatic function of MTMR2. Molecular analysis of
all previously reported cases of CMT4B1 with the presentation
of vocal cord paralysis has been associated with mutations in
the PH-GRAM domain (Houlden et al., 2001; Nouioua et al.,
2011; Zambon et al., 2017). Among the mutations occurring in
the phosphatase domain, p.Thr228fsTer275 resulted in truncated
MTMR2 with loss of the majority of the phosphatase domain
including active site residues of PtdIns (3,5)P2 binding (Asn330,
Asn355, Cys418, Arg423, Arg459, Arg463) (Begley et al., 2006)
and is associated with a rather severe phenotype (delayed
motor milestones, hypophonia, and skeletal deformities) but
less severe than seen in association with truncation of the
PH-GRAM domain. This is similar to the severe phenotype
observed for patient IV.2 from family 3 which harbors the
p.Arg364Ter mutation, predicted to result in loss of >50% of
the phosphatase domain including several active site residues
of PtdIns(3,5)P2 binding (Cys418, Arg423, Arg459, Arg463).
The milder phenotype observed in the brother might be due to
variable genomic background. The other two novel mutations
described in the current report, p.Phe498IlefsTer2 in family
1, and the splice site mutation c.1479+1G>A in family 2 as
well as one previously reported mutant p.Leu512TyrfsTer33
(Luigetti et al., 2013) occur in the tail of the phosphatase
domain, presumably resulting in less disruption of the enzymatic
function of MTMR2, however together with the predicted
complete loss of the C terminus including the coiled-coil domain
which is important for dimerization of MTMR2, patients still
exhibit a severe phenotype. Two mutations in the coiled-coil
domain (p.Gln590Ter, p.Trp583Ter) have also been linked to
a rather severe phenotype. This might be due to disruption
of the coiled-coil domain which is important for dimerization
of MTMR2 and also membrane association (Berger et al.,
2003). Mutations located after the coiled-coil domain may retain
the partial function of MTMR2 because CMT4B1 cases with
MTMR2mutations in this localization have a mild phenotype. It
was experimentally confirmed that p.Arg628ProfsTer18 protein
expression was still persisting as shown byMurakami et al., a faint
staining was also observed in the Schwann cells of both control
and patient sural nerve biopsy in MTMR2 immunoreactivity
(Murakami et al., 2013). This suggested that the disease-causing
mechanism of p.Arg628ProfsTer18 might be due to the loss
of the PDZ-binding motif, which is a motif important for
protein-protein interaction and whose exact role in protein
MTMR2 remains unclear. The mutant p.Gly103Glu in the PH-
GRAM domain and p.Arg283Trp in the phosphatase domain
with only single amino acid change resulted in rather a
mild phenotype (the patients are able to walk unassisted with
lightweight orthoses) suggesting MTMR2 might retain some
low level of activity. However, it is reported that p.Gly103Glu
has an impaired membrane association (Berger et al., 2003),
while p.Arg283Trp remains mainly as a monomer (Goryunov
et al., 2008) as dimerization is required for phosphorylation
activity, thus these two mutants still manifest as CMT4B1.
Nevertheless, the systematic experimental evaluation of the
mutations on protein expression, stability, and enzymatic
activity is required for a better understanding of the genotype-
phenotype correlations.
Thus, so far, several proteins involved in membrane
remodeling have been reported to be associated with
neuromuscular diseases. Among these, mutations in
myotubularin (MTM1), amphiphysin 2 (BIN1), and
dynamin 2 (DNM2) lead to different forms of centronuclear
myopathy (CNM). Myotubularins maintain the equilibrium
of phosphoinositides, amphiphysin senses the membrane
curvature and membrane remodeling while the dynamin 2 as
GTPase tubulate and cleave membranes. This suggests that
CNM is caused by mutations along a common pathological
pathway of membrane remodeling (Cowling et al., 2012).
Importantly, MTMRs also belong to the myotubularin family
with highly conserved domains (Figure 3), and mutations
in MTMRs cause Charcot-Marie-Tooth neuropathies. More
interestingly, mutations in dynamin 2 can also cause a dominant
form of Charcot-Marie-Tooth neuropathy, and recently it was
reported that mutations in another dynamin family member,
dynamin 1, cause encephalopathy (von Spiczak et al., 2017).
Moreover, mutations in INPP5K, which encodes the inositol
polyphosphate-5-phosphatase K, also known as SKIP (skeletal
muscle and kidney enriched inositol phosphatase), cause
congenital muscular dystrophy (Osborn et al., 2017; Wiessner
et al., 2017), with LGMD and neuropathic features. Therefore
the literature to date suggests that mutations in proteins involved
in membrane remodeling and trafficking might act through a
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FIGURE 4 | Illustration of neuromuscular disease-associated proteins involved in membrane remodeling. A high resolution figure can be found and downloaded
together with the Supplementary Material file. (A) The summarized known genes involved in both myopathy and neuropathy, which encode essential proteins for
phosphoinositides equilibrium, membrane remodeling and trafficking based on previous studies (Berger et al., 2006; Cowling et al., 2012). Proteins are classified
(Continued)
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FIGURE 4 | to groups based on the steps they are involved in membrane remodeling, and related diseases are also listed. (B) GO over-representation analysis with
input genes (n = 7) are selected from (A). Then 20 additional interactors added to the dataset, respectively according to their combined confidence score.
Protein-Protein interaction (PPI) information visualized with Cytoscape-string app. The network map shows 27 PPI which has the highest scores for the given set of
genes. In the map proteins are represented via nodes; the confidence scores are represented via interaction line colors; the enrichment terms are represented with
donut slices surrounding each node. (C) A total of 27 genes which have found to be the most significant in the StringDB analysis was used for the over-representation
analysis. First, 30 Gene-ontology Cellular Component terms enriched in the analysis are shown in (A). The colors represent the FDR adjusted p-values for each term.
(D) The cnet plot shows the linkage between genes and first 10 Gene Ontology Cellular Component (GO:CC) terms in which those genes are over-represented. The
size of GO term nodes represents the count of genes which are over-represented in that term.
shared pathological pathway (Figure 4A), with different diseases
likely manifesting due to a different degree of impact on protein
activity, regulatory functions, or tissue-specific expression,
and which thus requires further experimental validation. To
gain further evidence on this shared pathological pathway,
we performed a bioinformatic pathway analysis for the genes
in Figure 4. We used these genes as input to pull out at least
20 of their interaction partners for each of them to make a
dataset (details seen method description). From this dataset,
we performed GO enrichment analysis (Figures 4B–D and
Supplementary Figure 3) and results showed that most of
their interaction partners from these seven proteins are mainly
in membrane remodeling process such as clathrin-coated
pit/vesicle which is the function of dynamin in clathrin-coated
vesicle budding (Mettlen et al., 2009), or membrane ruﬄe,
cellular membrane leading edge from cellular compartment
analysis. Other common functions such as pre-/post-synapse,
synapse interaction are a common disease-causing mechanism
for neuropathy. Similar results were obtained from the biological
process analysis (Supplementary Figures 3A,B), we found that
the most involved processes were endocytosis, vesicle transport
and plasma membrane tubulation. And further confirmed from
the molecular function analysis (Supplementary Figure 3C),
results showed that the most significant enriched molecular
functions were the phosphoinositides metabolizing enzymatic
activity and membrane receptor binding or signaling. This
confirmed in conjunction to the published experimental
evidence (Sauvonnet et al., 2005; Chang-Ileto et al., 2011;
Taylor et al., 2011; Vazquez-Molina et al., 2018), on which have
elaborated above, that those genes listed in Figure 4A shared a
common pathway in the membrane remodeling and trafficking
pathway mediated by phosphoinositides.
It was recently shown that MTMR2 can rescue MTM1-
myopathy, with the short isoform being more effective (Raess
et al., 2017). Serotype 9 recombinant AAV vectors encoding
MTMR2 were injected into the tibialis anterior muscle of Mtm1-
deficient knockout mice, and a therapeutic effect was observed,
suggesting strategies aiming at increasing MTMR2 expression
levels in skeletal muscle may be beneficial in the treatment
of myotubular myopathy (Danièle et al., 2018). This might
be due to the highly conserved structures between MTM1
and MTMR2 resulting in phosphatase activity compensation.
Earlier it was shown in a mouse model that dynamin1
was critical for endocytic vesicle recycling under the intense
stimulus, while dynamin 2 or dynamin 3 expression were
able to partially or completely rescue the endocytic blockade
in DNM1-defective neurons (Raimondi et al., 2011). Thus,
these complementary and compensatory functions provide a
potential therapeutic strategy for the diseases resulting from
the common pathological pathway and suggests that one
gene may compensate for the loss of function by restoring
the overall balance of enzyme activities. However, whether
MTM1 could rescue MTMR2-related CMTB1, remains to
be investigated.
In conclusion, the cohort hereby reported further expands
the clinical and genetic spectrum of CMT4B1. Our patient
cohort from developing countries with limited regular access
to the state of the medical care represents the unmitigated
natural disease course of CMT4B1. Our results suggest that
localization of MTMR2 mutations in certain protein functional
domains could be an important determinant of clinical
manifestations. The combination of deep clinical phenotyping
and electrophysiological studies will be of continued importance
in order to guide genetic investigations in this disease.
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